论文部分内容阅读
目的：研究抵克力得预防重组人促红细胞生成素（ｒ Ｈｕ Ｅ Ｐ Ｏ）治疗维持性血液透析患者肾性贫血所诱发的顽固性高血压和血栓症的机制和疗效。方法：将１７ 例患者随机分为两组，治疗组１０ 例，在ｒ Ｈｕ Ｅ Ｐ Ｏ 治疗同时使用抵克力得，对照组 ７ 例，只使用ｒ Ｈｕ Ｅ Ｐ Ｏ。两组均治疗 １２ 周，然后比较治疗前后两组血液学及血流动力学指标的改变及临床疗效。结果：对照组血红蛋白（ Ｈｂ）、红细胞压积（ Ｈ Ｃ Ｔ）、平均血压（ Ｍ Ｂ Ｐ）和血小板计数（ Ｂ Ｐ Ｃ）均显著升高，出血时间（ Ｂ Ｔ）、凝血时间（ Ｃ Ｔ）显著缩短，并且发生高血压和内瘘血栓形成各３ 例，而治疗组 Ｈｂ、 Ｈ Ｃ Ｔ、 Ｂ Ｐ Ｃ 也显著升高，但 Ｃ Ｔ 及 Ｍ Ｂ Ｐ无明显改变，而且 Ｂ Ｔ 显著延长，无高血压及血栓症发生。结论：抵克力得可通过改变血小板的聚集功能，减轻ｒ Ｈｕ Ｅ Ｐ Ｏ 在尿毒症患者体内引起血液学和血流动力学上的不良反应，防止ｒ Ｈｕ Ｅ Ｐ Ｏ 治疗后高血压与血栓症的发生。
OBJECTIVE: To investigate the mechanism and efficacy of tacrolimus in the prevention of refractory hypertension and thrombosis induced by renal anemia in maintenance hemodialysis patients treated with recombinant human erythropoietin (r Hu E P O). Methods: Seventeen patients were randomly divided into two groups. Ten patients in the treatment group received tacrolimus in addition to r Hu E P O. Seven patients in the control group received r HuEPO alone. The two groups were treated for 12 weeks, and then compared before and after treatment hematological and hemodynamic changes in both groups and clinical efficacy. Results: The levels of hemoglobin (Hb), hematocrit (H C T), mean blood pressure (M B P) and platelet count (B P C) in the control group were significantly increased, the bleeding time (B T), clotting time ) Were significantly shortened and there were 3 cases of hypertension and fistula thrombosis. The Hb, H C T and B P C of the treatment group were also significantly increased, but the C T and M B P did not change significantly, and B T was significantly prolonged , No high blood pressure and thrombosis occurred. CONCLUSION: Triclodecline can reduce hematological and hemodynamic adverse effects caused by r Hu E P O in patients with uremia by changing the aggregation function of platelets, prevent hypertension and Thrombosis occurs.